Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;11(1):471-473.
doi: 10.3892/ol.2015.3852. Epub 2015 Nov 2.

Fanconi anemia-D1 due to homozygosity for the BRCA2 gene Cypriot founder mutation: A case report

Maria A Loizidou  1 , Andreas Hadjisavvas  2 , George A Tanteles  3 , Elena Spanou-Aristidou  3 , Kyriacos Kyriacou  2 , Violetta Christophidou-Anastasiadou  4
Affiliations

Fanconi anemia-D1 due to homozygosity for the BRCA2 gene Cypriot founder mutation: A case report

Maria A Loizidou et al. Oncol Lett. 2016 Jan.

Abstract

Fanconi anemia (FA) is a rare disorder characterized by multiple congenital malformations, progressive bone marrow failure and susceptibility to malignancies. Biallelic mutations in the breast cancer 2, early onset (BRCA2) gene are responsible for the FA-D1 subgroup, which accounts for ~3% of all the FA cases. Patients with biallelic BRCA2 mutations generally display a more severe phenotype, with earlier onset and increased incidence of leukaemia and other solid tumors, than other patients with FA. In the present report, the first Cypriot patient with FA-D1 is described, which is the fifth case of a homozygote for the same null allele reported thus far, and the third known case of neuroblastoma in association with FA-D1.

Keywords: Cyprus; Fanconi anemia; biallelic BRCA2 mutation; genotype-phenotype correlation; neuroblastoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362:1909–1919. doi: 10.1056/NEJMra0809889. - DOI - PMC - PubMed
    1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al., editors. Bethesda, MD: Apr, 2012. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. based on November 2011 SEER data submission, posted to the SEER web site.
    1. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: Histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19:428–432. doi: 10.1097/00043426-199709000-00004. - DOI - PubMed
    1. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23:6459–6465. doi: 10.1200/JCO.2005.05.571. - DOI - PubMed
    1. Castleberry RP, Pritchard J, Ambros P, Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B, Dicks-Mireaux C, Frappaz D, et al. The International Neuroblastoma Risk Groups (INRG): A preliminary report. Eur J Cancer. 1997;33:2113–2116. doi: 10.1016/S0959-8049(97)00202-5. - DOI - PubMed

LinkOut - more resources